These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 21080856)

  • 21. Use of dihydroergotamine (DHE) should be restricted to no more than twice a week.
    Tfelt-Hansen PC; Diener HC
    Headache; 2014 Oct; 54(9):1523-5. PubMed ID: 24862945
    [No Abstract]   [Full Text] [Related]  

  • 22. Dihydroergotamine mesylate-loaded dissolving microneedle patch made of polyvinylpyrrolidone for management of acute migraine therapy.
    Tas C; Joyce JC; Nguyen HX; Eangoor P; Knaack JS; Banga AK; Prausnitz MR
    J Control Release; 2017 Dec; 268():159-165. PubMed ID: 29051065
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Exacerbation of headache during dihydroergotamine for chronic migraine does not alter outcome.
    Eller M; Gelfand AA; Riggins NY; Shiboski S; Schankin C; Goadsby PJ
    Neurology; 2016 Mar; 86(9):856-9. PubMed ID: 26843569
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness of subcutaneous dihydroergotamine by home injection for migraine.
    Becker WJ; Riess CM; Hoag J
    Headache; 1996 Mar; 36(3):144-8. PubMed ID: 8984085
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inpatient treatment of status migraine with dihydroergotamine in children and adolescents.
    Kabbouche MA; Powers SW; Segers A; LeCates S; Manning P; Biederman S; Vaughan P; Burdine D; Hershey AD
    Headache; 2009 Jan; 49(1):106-9. PubMed ID: 19125879
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ergot pharmacology and alternative delivery systems for ergotamine derivatives.
    Goldstein J
    Neurology; 1992 Mar; 42(3 Suppl 2):45-6. PubMed ID: 1557192
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Transformed migraine--chronic daily headache].
    Bøe MG; Monstad P
    Tidsskr Nor Laegeforen; 1999 Nov; 119(29):4311-3. PubMed ID: 10667127
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MAP0004, orally inhaled DHE: a randomized, controlled study in the acute treatment of migraine.
    Aurora SK; Silberstein SD; Kori SH; Tepper SJ; Borland SW; Wang M; Dodick DW
    Headache; 2011 Apr; 51(4):507-17. PubMed ID: 21457235
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aprepitant for the management of nausea with inpatient IV dihydroergotamine.
    Chou DE; Tso AR; Goadsby PJ
    Neurology; 2016 Oct; 87(15):1613-1616. PubMed ID: 27629088
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The pharmacology of ergotamine and dihydroergotamine.
    Silberstein SD
    Headache; 1997; 37 Suppl 1():S15-25. PubMed ID: 9009470
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rescue therapy for acute migraine, part 1: triptans, dihydroergotamine, and magnesium.
    Kelley NE; Tepper DE
    Headache; 2012 Jan; 52(1):114-28. PubMed ID: 22211870
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Symptomatic treatment of migraine in children: a systematic review of medication trials.
    Damen L; Bruijn JK; Verhagen AP; Berger MY; Passchier J; Koes BW
    Pediatrics; 2005 Aug; 116(2):e295-302. PubMed ID: 16061583
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Is the Generally Held View That Intravenous Dihydroergotamine Is Effective in Migraine Based on Wrong "General Consensus" of One Trial? A Critical Review of the Trial and Subsequent Quotations.
    Bekan G; Tfelt-Hansen P
    Headache; 2016 Oct; 56(9):1482-1491. PubMed ID: 27595607
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intravenous dihydroergotamine for inpatient management of refractory primary headaches.
    Nagy AJ; Gandhi S; Bhola R; Goadsby PJ
    Neurology; 2011 Nov; 77(20):1827-32. PubMed ID: 22049203
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cerebral reactivity in migraine patients measured with functional near-infrared spectroscopy.
    Pourshoghi A; Danesh A; Tabby DS; Grothusen J; Pourrezaei K
    Eur J Med Res; 2015 Dec; 20():96. PubMed ID: 26644117
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical experience with patient administered subcutaneous dihydroergotamine mesylate in refractory headaches.
    Klapper JA; Stanton J
    Headache; 1992 Jan; 32(1):21-3. PubMed ID: 1372884
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized, double blind, placebo-controlled study of MAP0004 in adult patients with migraine.
    Aurora SK; Rozen TD; Kori SH; Shrewsbury SB
    Headache; 2009 Jun; 49(6):826-37. PubMed ID: 19545249
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Episodic acute migraine treatment.
    Tepper D
    Headache; 2014; 54(10):1681-2. PubMed ID: 25399860
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Journal Club: Exacerbation of headache during dihydroergotamine for chronic migraine does not alter outcome.
    Woldeamanuel YW; O'Hare M; DeSouza DD; Cowan RP
    Neurology; 2016 Oct; 87(16):e196-e198. PubMed ID: 27754915
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dihydroergotamine: a review of its use in the treatment of migraine and other headaches.
    Scott AK
    Clin Neuropharmacol; 1992 Aug; 15(4):289-96. PubMed ID: 1516074
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.